Biotech stocks have had a rough start to 2024, but don’t believe the headlines—the industry is far from dead. While some investors panic over short-term setbacks, smart money knows that breakthroughs in biotech don’t wait for perfect market conditions. Medicine keeps advancing, and these companies are leading the charge.
From game-changing cancer drugs to genetic breakthroughs and mental health revolutions, these five biotech stocks aren’t just surviving the downturn—they’re thriving. If you’re looking for stocks that could dominate the future, these are the ones to watch.
1. Halozyme Therapeutics (HALO): The Future of Drug Delivery
Big Pharma has a problem—patients hate needles and IV drips. Halozyme is fixing that with its Enhanze technology, which delivers blockbuster drugs through a simple subcutaneous injection. That means faster treatment times, fewer hospital visits, and a better patient experience.
And guess who’s already using it? Johnson & Johnson, Roche, and other pharmaceutical giants.
? Q4 sales jumped 30% to $298 million
? Earnings surged 54% to $1.26 per share
? 2025 revenue forecast: up to $1.225 billion
With strong growth, a massive pipeline, and Big Pharma’s backing, Halozyme isn’t just a biotech company—it’s the backbone of a new era in medicine.
? Wall Street is finally catching on. Will you?
2. Catalyst Pharmaceuticals (CPRX): The Rare Disease Powerhouse
Catalyst doesn’t chase hyped-up miracle drugs that never make it past trials. Instead, it focuses on rare diseases—a lucrative niche with high demand and little competition.
Its flagship drug, Firdapse, treats a rare neuromuscular disorder, and thanks to a new deal with Teva, it’s now protected from generic competition until 2035. That’s more than a decade of revenue dominance.
? Q4 revenue up 30% to $141.8 million
? Earnings jumped 32% to 70 cents per share
? 2024 revenue outlook: Up to $565 million
With tight FDA regulations keeping competitors out, Catalyst has built a monopoly in its space—and investors who get in early could reap the rewards.
? Somebody’s going to profit from this. The question is, will it be you?
3. Exelixis (EXEL): The Quiet Giant in Cancer Treatment
While other biotech companies chase the next big thing, Exelixis is already saving lives. It dominates the cancer treatment market with Cabometyx, a drug for kidney, liver, and thyroid cancers that’s becoming the gold standard in oncology.
And yet, despite blowout earnings, Exelixis is still under the radar.
? Q4 revenue climbed 18% to $567 million
? Earnings rocketed 67% to 55 cents per share
? 2025 revenue forecast: Up to $2.25 billion
Cancer treatments aren’t going out of style anytime soon, and with a pipeline packed with new drugs, Exelixis is just getting started.
? Why aren’t more people talking about this stock? Maybe they don’t want you to know.
4. Alkermes (ALKS): The Mental Health Revolution No One’s Watching
The world is finally waking up to the mental health crisis, and Alkermes is leading the charge with next-gen treatments for bipolar disorder, schizophrenia, and addiction.
Its three major drugs—Lybalvi, Aristada, and Vivitrol—are in high demand, and sales are surging.
? Lybalvi sales soared 37% to $77 million
? Vivitrol revenue skyrocketed 31% to $134.1 million
? Shares broke out of a major technical pattern, signaling momentum
As mental health funding increases and the stigma around treatment fades, Alkermes is positioned to own this space.
? The mental health boom is here—will you profit from it or just read about it?
5. GeneDx (WGS): The DNA Testing Stock That’s Changing Medicine Forever
What if doctors could predict diseases before they happen? What if newborns could be diagnosed with genetic conditions within 48 hours?
That’s not sci-fi—it’s GeneDx.
GeneDx is revolutionizing medicine with next-level genetic testing that could completely change how we diagnose and treat diseases.
? Q4 revenue exploded 65% to $95.6 million
? Earnings flipped positive, reaching 77 cents per share
? New rapid DNA test sends results in 48 hours—game changer for hospitals
After announcing its latest breakthrough, the stock skyrocketed 48% in a single day.
? Wall Street is waking up. Have you?
The Bottom Line: Biotech’s Biggest Winners Are Just Getting Started
While some investors are panicking over short-term dips, these five biotech companies are building the future of medicine.
? Life-saving drugs. Billion-dollar breakthroughs. Cutting-edge technology.
The next wave of biotech innovation is already happening. The only question is:
? Are you paying attention?
Sponsored by: $EDXC – Endexx Corporation https://endexx.com/
